On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada had authorized COMIRNATY Original & Omicron BA.4/BA.5 as a 30-ﾵg booster dose for individuals ages 12 years and older.

An application for an Omicron BA.4/BA.5-adapted bivalent vaccine for children 5 through 11 years of age was planned for submission to Health Canada for review.